A study of R435(Bevacizmab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer

INTERVENTION: Intervention name : Bevacizumab Dosage And administration of the intervention : Infusion CONDITION: Colon cancer PRIMARY OUTCOME: Disease ‐free survival, INCLUSION CRITERIA: INCLUSION CRITERIA: ‐ >= 18 years of age, adult patients ‐ documented colon carcinoma ‐ not a candidate for (neo) adjuvant radiotherapy ‐ curative surgery not less than 4 and not more than 8 weeks prior to study randomization. Exclusion criteria: ‐ evidence of metastatic disease ‐ previous anti‐angiogenic treatment for any malignancy ‐previous cytotoxic chemotherapy, radiotherapy, or immunotherapy for colon cancer ‐ pregnant or lactating women ‐ fertile men, or women of childbearing potential, not using adequate contraception ‐ major surgical procedures, open biopsy, or significant traumatic injury, within 28 days prior to study treatment start ‐ current or recent treatment (within 28 days prior to randomization) with another investigational drug, or participation in another investigational study